Share on StockTwits

CareFusion (NYSE:CFN) reached a new 52-week high during trading on Tuesday , Analyst Ratings Network reports. The company traded as high as $45.52 and last traded at $45.33, with a volume of 1,701,182 shares trading hands. The stock had previously closed at $44.35.

A number of analysts have recently weighed in on CFN shares. Analysts at Topeka Capital Markets initiated coverage on shares of CareFusion in a research note on Thursday, June 12th. They set a “hold” rating and a $44.00 price target on the stock. Separately, analysts at Raymond James raised their price target on shares of CareFusion from $48.00 to $50.00 in a research note on Monday, May 19th. They now have a “strong-buy” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of CareFusion in a research note on Wednesday, May 7th. They now have a $41.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. CareFusion has an average rating of “Buy” and an average target price of $42.45.

The stock has a 50-day moving average of $43.08 and a 200-day moving average of $40.79. The company has a market cap of $9.383 billion and a price-to-earnings ratio of 24.80.

CareFusion (NYSE:CFN) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by $0.02. The company had revenue of $968.00 million for the quarter, compared to the consensus estimate of $986.67 million. During the same quarter in the previous year, the company posted $0.59 earnings per share. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. On average, analysts predict that CareFusion will post $2.31 earnings per share for the current fiscal year.

CareFusion Corporation (NYSE:CFN) is a global medical technology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.